CA3194818A1 - Intranasal administration of suramin for treating nervous system disorders - Google Patents

Intranasal administration of suramin for treating nervous system disorders

Info

Publication number
CA3194818A1
CA3194818A1 CA3194818A CA3194818A CA3194818A1 CA 3194818 A1 CA3194818 A1 CA 3194818A1 CA 3194818 A CA3194818 A CA 3194818A CA 3194818 A CA3194818 A CA 3194818A CA 3194818 A1 CA3194818 A1 CA 3194818A1
Authority
CA
Canada
Prior art keywords
suramin
mice
nervous system
disorder
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3194818A
Other languages
English (en)
French (fr)
Inventor
Michael Derby
Zachary ROME
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PaxMedica Inc
Original Assignee
PaxMedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PaxMedica Inc filed Critical PaxMedica Inc
Publication of CA3194818A1 publication Critical patent/CA3194818A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3194818A 2020-10-22 2021-10-20 Intranasal administration of suramin for treating nervous system disorders Pending CA3194818A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104350P 2020-10-22 2020-10-22
US63/104,350 2020-10-22
PCT/US2021/055908 WO2022087174A1 (en) 2020-10-22 2021-10-20 Intranasal administration of suramin for treating nervous system disorders

Publications (1)

Publication Number Publication Date
CA3194818A1 true CA3194818A1 (en) 2022-04-28

Family

ID=81289355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3194818A Pending CA3194818A1 (en) 2020-10-22 2021-10-20 Intranasal administration of suramin for treating nervous system disorders

Country Status (8)

Country Link
US (1) US20230390226A1 (cg-RX-API-DMAC10.html)
EP (1) EP4229035A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546923A (cg-RX-API-DMAC10.html)
CN (1) CN116802174A (cg-RX-API-DMAC10.html)
AU (1) AU2021366666A1 (cg-RX-API-DMAC10.html)
CA (1) CA3194818A1 (cg-RX-API-DMAC10.html)
IL (1) IL302223A (cg-RX-API-DMAC10.html)
WO (1) WO2022087174A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11080495B2 (en) * 2018-10-25 2021-08-03 Unified Information Devices, LLC Animal motion and temperature monitoring
AU2021319064A1 (en) * 2020-07-29 2023-03-23 Perfect Daylight Limited Methods of manufacture of suramin
US20230390223A1 (en) * 2020-10-22 2023-12-07 Paxmedica, Inc. Administration of antipurinergic compositions for treating nervous system disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148262A1 (en) * 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
WO2018148580A1 (en) * 2017-02-09 2018-08-16 Perfect Daylight Limited Methods for autism spectrum disorder pharmacotherapy
JP7749169B2 (ja) * 2019-06-07 2025-10-06 クヴァトリス セラピューティクス， インコーポレイテッド 中枢神経系障害を処置するための組成物および方法

Also Published As

Publication number Publication date
CN116802174A (zh) 2023-09-22
JP2023546923A (ja) 2023-11-08
IL302223A (en) 2023-06-01
EP4229035A4 (en) 2024-07-31
WO2022087174A1 (en) 2022-04-28
AU2021366666A9 (en) 2024-02-08
EP4229035A1 (en) 2023-08-23
US20230390226A1 (en) 2023-12-07
AU2021366666A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
US20230390226A1 (en) Intranasal administration of suramin for treating nervous system disorders
JP2017533276A (ja) 認知低下を処置するための方法
ES2788598T3 (es) Métodos y composiciones para tratar enfermedades neurodegenerativas
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
ES2891306T3 (es) Combinación de ibudilast y riluzol y métodos de utilización de los mismos
CN114340597B (zh) 用于治疗中枢神经系统障碍的组合物和方法
CN114507205A (zh) 二氢杨梅素四氢吡咯复合物及其制备方法和应用
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents
US20150335629A1 (en) Methods Of Treating Fragile X Syndrome And Related Disorders
CN112043700A (zh) 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用
HK40073161B (en) Compositions and methods for treating central nervous system disorders
HK40073161A (en) Compositions and methods for treating central nervous system disorders
WO2026052068A1 (zh) 药物组合物的用途
TW201622714A (zh) 以苯氧烷基羧酸抑制或治療肌萎縮性脊髓側索硬化症之方法
JPWO2005027968A1 (ja) ダウン症候群治療剤

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250818

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428